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C57BL/6 (B6) mice infected with LP-BM5 retroviruses develop disease, including an immunodeficiency
similar to AIDS. This disease, murine AIDS (MAIDS), is inhibited by in vivo anti-CD154 monoclonal antibody
treatment. The similar levels of insusceptibility of CD40/ and CD154/ B6 mice indicate that CD154/CD40
molecular interactions are required for MAIDS. CD4 T and B cells, respectively, provide the CD154 and
CD40 expression needed for MAIDS induction. Here, the required CD154/CD40 interaction is shown to be
independent of CD80 and CD86 expression: CD80/CD86/ B6 mice develop MAIDS after LP-BM5 infection.
After infection with the LP-BM5 murine leukemia retrovirus
isolate, certain inbred strains of mice, such as the highly sus-
ceptible C57BL/6 (B6) strain, develop a complex disease syn-
drome which includes immunodeficiency. This murine leuke-
mia retrovirus mixture contains ecotropic, recombinant mink
cell cytopathic-focus-inducing, and replication-negative/defec-
tive viruses, with the defective genome serving as the proximal
agent causing the syndrome (2, 9, 17, 18, 31). Since many
features of LP-BM5-induced disease are similar to those seen
in human immunodeficiency virus-infected individuals, this
syndrome has been designated murine AIDS (MAIDS).
Disease similarities include activation-related parameters such
as hypergammaglobulinemia (hyper-Ig), splenomegaly, and
lymphadenopathy; immunodeficiency-related responses in-
volving severely dampened T- and B-cell responses; increased
susceptibility to infection, disease progression, and death when
exposed to environmental pathogens that normally cause lim-
ited infections; and the development of terminal B-cell lym-
phomas (5, 7, 22, 23, 25, 29, 30, 32, 40).
According to previous studies, B6 mice infected by LP-BM5
after in vivo depletion of either CD4 T cells or B cells do not
develop MAIDS (7, 39, 40). These studies, however, did not
address the possibility that the involvement of other cellular
subsets is required for MAIDS pathogenesis and did not ex-
perimentally address the possible interaction of these subsets
nor the molecular bases for interaction. Given that CD154/
CD40 ligation has been shown to be critical in many immune
responses involving the interaction of CD4 T cells with pro-
fessional antigen-presenting cells (APC) (1, 19, 20, 33, 35), we
recently examined the involvement of CD154/CD40 interac-
tions in the LP-BM5-induced initiation and progression of
MAIDS. In one approach, Green et al. treated LP-BM5-in-
fected mice in vivo with anti-CD154 monoclonal antibody
(MAb) (13, 15). By interrupting CD154/CD40 signaling by
anti-CD154 treatment during the first week postinfection (13)
or starting at 3 to 4 weeks after LP-BM5 infection with a
chronic MAb treatment schedule (15), MAIDS-associated
splenomegaly, hyper-Ig, and immunodeficiency were efficiently
inhibited. In addition, Green et al. and other researchers have
shown that CD154 (14) and CD40 (14, 21) knockout (ko) B6
mice are resistant to LP-BM5-induced MAIDS. Thus, CD154/
CD40 interactions are necessary for both the initiation and the
progression of MAIDS. Most recently, we have defined the
cellular subsets required to provide CD154 or CD40 expres-
sion for MAIDS pathogenesis (14). Using a series of adoptive
transfers into B6 nude mice, we demonstrated that CD4, but
not CD8, T cells must express CD154 for induction of
MAIDS. Analogous experiments involved successful reconsti-
tution of disease susceptibility by transfer of donor CD40 B
cells, but not CD40 macrophages or dendritic cells, into nor-
mally MAIDS-resistant, LP-BM5-infected CD40 ko mice.
Although ligation of CD40 on professional APC induces a
number of overlapping signal transduction pathways, a central
paradigm is that many of the ultimate functional consequences
are determined by the known upregulation of the costimula-
tory ligands for CD28 and CTLA-4, namely, B7-1 (CD80) and
B7-2 (CD86) (6, 20, 34–36, 38). To determine whether the
requirement for CD40 ligation by CD154 for MAIDS patho-
genesis depends on this classic upregulation of CD80 and/or
CD86, we infected B6.CD80/CD86 double-ko mice, which
were originally derived as previously described (3), with LP-
BM5 virus. Infected mice were assessed 6 to 11 weeks postin-
oculation via the standard panel of readouts by which Green et
al. and other researchers have evaluated MAIDS pathogenesis
(2, 5, 7, 9, 13–15, 18, 20, 31). The spleen weight for infected
CD80/CD86 ko mice more than doubled relative to that of
uninfected ko mice, whereas the spleen weight for infected B6
mice was about six times that for uninfected B6 mice (Fig. 1).
The finding of the relative increase in spleen weight in LP-
BM5-infected B6 wild-type (WT) versus B6 CD80/CD86 ko
mice was repeated in a second initial experiment.
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All other disease parameters, including both those indicative
of the activational events and those indicative of the immuno-
suppressive effects, clearly indicated that B6 CD80/CD86 dou-
ble-ko mice are susceptible to LP-BM5-induced MAIDS. For
example, the ability to generate allogeneic CTL responses was
severely impaired, as one index of T-cell immunodeficiency
(Fig. 2). Spleen cells from either uninfected or infected CD80/
CD86 ko or WT (H-2b) B6 mice were cultured in vitro with
irradiated LB27.4 (H-2bxd) cells, and 6 days later allogeneic
(anti-H-2d) CTL activity was assessed by standard 51Cr release
assays. As evidenced by both analysis of individual mice (Fig.
2A) and analysis of the mean activity levels ( standard devi-
ations) of mouse groups (Fig. 2B), similar levels of dramatic
loss in the ability to generate allogeneic CTL responses were
seen for the CD80/CD86 ko and WT LP-BM5-infected mice.
Similar results were observed in the second initial experiment.
Thus, LP-BM5-infected CD80/CD86 ko mice are clearly sus-
ceptible to MAIDS pathogenesis. However, it was unclear
whether their susceptibility was as complete as that seen in
infected B6 mice. That is, using splenomegaly as representative
of the activational events of MAIDS, less disease was seen,
whereas levels of allogeneic CTL generation, along with those
of lipopolysaccharide (LPS) and concanavalin A (ConA) re-
sponsiveness (data not shown), which represent the immuno-
deficiency parameters, suggested nearly equivalent levels of
disease in these two mouse strains. To eliminate the possibility
that the precise virus dose usually employed was responsible
for this potential differential disease penetrance as revealed by
activational versus immunosuppressive parameter values, a vi-
rus titration experiment was also conducted. The results were
clear and argued against a critical role for virus dose (data not
shown). Although somewhat higher or lower levels of disease
were obtained by varying the inoculating virus dose, the rela-
tionship of the different disease parameters between B6 and
B6.CD80/CD86 ko mice was maintained. Similarly, to address
the expression and spread of the causative defective virus, the
viral loads of infected B6 and B6.CD80/CD86 ko mice were
assessed. RNA was isolated from splenic tissue, and reverse-
transcribed cDNA was subjected to real-time quantitative PCR
amplification by using previously described primers (12) with
specificity for the MAIDS-defective gag gene. We found
roughly similar amounts of defective gag RNA copies in LP-
BM5-infected CD80/CD86 ko and B6 mice (Fig. 3), and in a
repeat experiment (data not shown) there was almost no dif-
ference in the amounts of defective gag RNA copies for in-
fected CD80/CD86 ko versus B6 mice.
To further evaluate MAIDS disease susceptibility and its
degree of severity in LP-BM5-infected B6 CD80/CD86 ko
mice, it was important to more carefully consider comparisons
to the disease phenotypes of infected B6.CD154 and B6.CD40
FIG. 1. Spleen size (by weight) at 8.5 weeks postinfection of LP-
BM5-infected B6 CD80/CD86 ko mice and B6 WT mice. Mean spleen
sizes and standard deviations represent four mice per group. *, P 
0.05 by the Student t test.
FIG. 2. Allogeneic CTL response (at 8.5 weeks postinfection) of spleen cells from LP-BM5-infected B6 CD80/CD86 ko mice and B6 WT mice.
At the terminal time point, mice were sacrificed and their spleen cells (H-2b) were mixed with irradiated LB27.4 tumor cells (H-2 b/d); 6 days later,
the resulting effector cells were used in a 51Cr release assay against P815 target cells (anti-H-2d). Values for individual mice (A) and mean 
standard deviation (B) percent specific lysis values are shown. *, P  0.05 by the Student t test; E:T, effector-to-target cell ratio.
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ko mice. In particular, Green et al. (14) and the laboratory of
Kikutani et al. (21) have reported that while CD40/ mice are
essentially MAIDS resistant upon infection with LP-BM5, they
show some limited signs of MAIDS compared to fully resistant
strains such as nude and CD154/ mice. Although all stan-
dard disease parameters were assessed, we emphasize here
those not already presented in Fig. 1 and 2.
In experiments which included CD154 ko and CD40 ko
mice, we again found that spleen weights for infected CD80/
CD86 ko mice were about twofold higher than those of unin-
fected CD80/CD86 ko mice (data not shown). Along with
splenomegaly as an indicator of the activational aspects of
MAIDS, we measured levels of serum immunoglobulin G2a
(IgG2a) and IgM as a part of the generalized hyper-Ig of
MAIDS. At an early time point (6 weeks postinfection), IgM
levels were about eightfold higher for infected than for unin-
fected CD80/CD86 ko mice (Fig. 4A), with similar results
observed in a replicate experiment comparing these four
mouse strains. For prototype susceptible B6 mice, the increse
to a similar absolute value for 6-week IgM levels was somewhat
greater at 13-fold upon infection, but this was merely due to
different baseline IgM levels. The increases for CD80/CD86 ko
and B6 mice were strongly indicative of the presence of
MAIDS, especially in comparison to the IgM values for in-
fected CD154 and CD40 ko mice, which were essentially the
same as those for the uninfected controls. Absolute serum
IgG2a levels at 6 weeks postinfection were higher for infected
B6 mice than those for infected CD80/CD86 ko mice, which
were similar to those for CD40 ko mice. CD40 ko mice have
previously been reported to demonstrate partially elevated Ig
levels upon LP-BM5 infection (14, 21). However, at 9 weeks
postinfection, IgG2a and IgM levels for CD80/CD86 ko and B6
mice were similarly elevated and clearly distinguishable from
those of the other ko strains, consistent with equivalent disease
only in these two strains (Fig. 4B).
The responses to mitogens for T versus B cells were also
evaluated as indices of immunodeficiency. Like those from B6
mice, spleen cells from infected CD80/CD86 ko mice had
greatly diminished ConA and LPS responses, i.e., only approx-
imately 20% of those for uninfected CD80/CD86 ko mice (Fig.
5). In contrast, ConA responses for both infected CD154 and
CD40 ko mice were consistently nearly identical to those for
their uninfected counterparts. Similarly, LPS responses for in-
fected CD154 ko mice were largely unaffected (85% of those
for uninfected CD154 ko mice). The LPS response for infected
CD40 ko mice was about 60% of that for uninfected CD40 ko
mice, as discussed above (14, 21). In summary, for the mitogen
studies, infected CD80/CD86 ko mice were clearly immunode-
ficient compared to the MAIDS-resistant CD154/ and
CD40/ controls. As with allogeneic CTL generation as an
index of immunodeficiency, the mitogen responses of CD80/
CD86 ko mice were nearly as severely diminished as those of
B6 mice, the prototype susceptible strain.
In conclusion, the data clearly demonstrate that the CD80/
CD86/ strain is MAIDS susceptible. For this double-ko
strain, all MAIDS readouts, including those measuring activa-
tional parameters, readily distinguished uninfected mice from
those undergoing disease progression in response to LP-BM5
infection (Fig. 1 and 4). Furthermore, CD80/CD86 ko spleen
cells from infected mice displayed similarly dramatic levels of
immunodeficiency (Fig. 2 and 5), and cell subpopulation
FIG. 3. Viral load in uninfected () and infected ( [9 weeks
postinfection]) CD80/CD86 ko and WT mouse spleen tissue. Total
RNA was isolated and DNase I treated. One microgram of DNA-free
RNA was reverse transcribed to cDNA by using random hexamer
priming. Real-time PCR was performed for BM5-defective gag RNA
by amplifying 0.5 l (300 pg) of cDNA in the presence of SYBR
Green stain on an iCycler iQ instrument (Bio-Rad). Amplification
conditions were 95°C for 8 min followed by 40 cycles of 94°C for 15 s,
63°C for 45 s, and 72°C for 15 s. The number of PCR cycles required
for SYBR green fluorescence to cross a threshold at which there was
a significant increase in change in fluorescence Ct-threshold cycle) was
measured by using iCycler iQ software. Total cDNA input was nor-
malized to -actin expression, which was measured by using primers
(forward, 5-agagggaaatcgtgcgtgac; reverse, 5-caatagtgatgacctggccgt)
in parallel PCRs. Copy numbers of BM5-defective gag RNA were
determined using a standard curve that was generated by using the
cloned 246-bp defective gag amplicon. In a repeat experiment, the
numbers of BM5-defective gag RNA copies found in spleens of CD80/
CD86 ko and B6 mice were nearly identical.
FIG. 4. Serum IgM and IgG2a response (at 6 weeks [A] and 9
weeks [B] postinfection) in LP-BM5-infected B6.CD80/CD86 ko,
CD154 ko, CD40 ko, and WT mice. Enzyme-linked immunosorbent
assays were conducted by using goat anti-mouse IgM and IgG2a cap-
ture antibodies followed by standard reagents, as previously described
(12–15). *, P  0.05 by the Student t test.
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changes, based on Thy 1.2, CD4, and CD8 expression at 11
weeks postinfection with LP-BM5, compared to prototype sus-
ceptible B6 mice (data not shown). Consistent with these data,
there was no evidence for differences in the viral loads for the
causative defective genome in the B6 and B6.CD80/CD86 ko
strains (Fig. 3).
It is worth discussing further the degree of MAIDS suscep-
tibility in LP-BM5-infected CD80/CD86 ko mice, particularly
respecting the readouts indicating activational events. The
spleen size of infected CD80/CD86 ko mice was consistently
about twofold larger than that of the uninfected ko mice, while
the spleen size of infected WT B6 mice was approximately
sixfold larger than that of uninfected B6 mice (Fig. 1). This
relative difference in splenomegaly may be the result of an
intrinsic defect of (uninfected) CD80/CD86 ko spleen cells in
response to certain stimuli that induce proliferation, for exam-
ple, to ConA stimulation. As has been reported previously
(37), we consistently found that after stimulation with ConA,
spleen cells from uninfected CD80/CD86 ko mice proliferated
approximately 10-fold less than uninfected WT B6 mouse
spleen cells whereas LPS mitogenesis was normal (data not
shown). By the addition of irradiated WT (CD80/CD86) B6
spleen cells as APC, we were able to restore the level of
response of CD80/CD86 ko mouse responder T cells to that of
WT B6 T cells. But the percent inhibition of ConA respon-
siveness caused by LP-BM5 infection of CD80/CD86 ko mice
was virtually the same with or without WT APC. This lack of
full proliferative potential of CD80/CD86 ko T cells in re-
sponse to stimuli mediated by cell-to-cell interaction is in keep-
ing with various functional deficits that have been reported for
this double ko strain (8, 28, 37). This reduction of levels of cell
proliferation and/or splenomegaly in response to LP-BM5 in-
fection was not cell subpopulation specific, however, based on
our assessment by flow cytometry of phenotypic markers de-
fining these subsets (data not shown).
We also observed somewhat less disease penetrance in
CD80/CD86 ko mice with respect to certain aspects of the
activational parameter, hyper-Ig (Fig. 4). Consistent with these
findings, the lab of Swain has also reported data which suggest
that the activational versus immunodeficiency aspects of
MAIDS can be separated in certain settings (16). However, in
our studies, the less than fully increased serum Ig levels for
infected CD80/CD86/ mice were isotype and time point
dependent. Certainly, by the terminal time point, the hyper-Ig
readouts were as fully developed for infected CD80/CD86/
as for B6 mice (Fig. 4).
Our results indicating the clear independence of MAIDS
susceptibility and CD80/CD86 expression are seemingly at
odds with recent reports that soluble CTLA4Ig treatment can
inhibit MAIDS. In one study, very partial inhibition was ob-
served with delayed kinetics of MAIDS pathogenesis after in
vivo chronic treatment with soluble CTLA4Ig (10). Alterna-
tively, the transgenic overexpression of CTLA4Ig (11) led to
more substantial, though still transient and incomplete, inhi-
bition of MAIDS. The reasons for this apparent discrepancy
are unclear. First, however, a different MAIDS virus isolate
(Du5H) was employed versus our use of LP-BM5. Second,
even though a greater resistance to MAIDS was observed as a
result of the continuous transgenic expression of CTLA4Ig
(11) compared to that observed as a result of the periodic
injection of soluble CTLA4Ig (10), observable disease still
occurred, especially at later time points, and there was no
decrease in defective viral load (11). Third, it has been sug-
gested that some of the observed functional effects of
CTLA4Ig treatment may not be due simply to blockade of
CD80/CD86 but are rather a consequence of the engagement
of the Ig tail with Fc receptors or the complement system (24).
Finally, although we are unaware of any supporting physiolog-
ical data, it is theoretically possible that additional novel li-
gands for CD28/CTLA-4 exist whose function is blocked by
CTLA4Ig, perhaps with induction of subsequent regulatory
events (4). In addition, our results do not preclude the involve-
ment of other previously described receptor-ligand pairs that
may also be considered broadly as costimulatory molecules.
For example, chronic in vivo MAb treatment with anti-LFA-1
and/or anti-ICAM-1 partially reduced MAIDS severity to a
variable extent (26).
Because CD80/CD86 interactions are not necessary for the
LP-BM5-induced cascade of cellular and molecular responses
characteristic of MAIDS pathogenesis, further investigation of
upstream activational signaling events initiated by CD154/
CD40 ligation will obviously be needed to shed further light on
the molecular basis for this requirement for disease.
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FIG. 5. Spleen cell response to T-cell mitogen (ConA) and B-cell
mitogen (LPS). Mice were left untreated () or were subjected to
LP-BM5 virus infection for 9 (A) or 10 (B) weeks (). After the mice
were sacrificed, spleen cell suspensions were cultured for 3 days with 2
g of ConA/ml and, in the case of the CD80/CD86 ko mouse respond-
ers, irradiated WT B6 spleen cells (responder/spleen cell ratio, 10:1) to
provide CD80/CD86-expressing APC, which are required for T-cell
proliferation as previously reported (37), or with 10 g of LPS/ml or
with medium only. Cellular proliferation was assessed by a terminal 6-h
incorporation of [3H]thymidine. Mean values for delta counts per
minute  standard deviations represent four mice per group. *, P 
0.05 by the Student t test.
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